Lineage Cell Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Lineage Cell Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$3.03M, a 57.3% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$20.1M, a 12.8% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$21.5M, a 18.2% increase from 2022.
  • Lineage Cell Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$26.3M, a 38.9% increase from 2021.
  • Lineage Cell Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$43M, a 108% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$20.1M -$3.03M +$4.08M +57.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$24.2M -$5.76M -$531K -10.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$23.7M -$6.54M -$2.17M -49.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$21.5M -$4.78M +$1.58M +24.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$23.1M -$7.11M -$1.04M -17.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$22M -$5.23M +$1.53M +22.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$23.6M -$4.37M +$2.72M +38.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$26.3M -$6.35M +$22.6M +78.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$48.9M -$6.07M +$1.75M +22.4% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-07
Q2 2022 -$50.7M -$6.76M -$1.98M -41.2% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-07
Q1 2022 -$48.7M -$7.09M -$5.67M -400% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-07
Q4 2021 -$43M -$29M -$31M -1527% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$12M -$7.82M -$63K -0.81% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-09
Q2 2021 -$11.9M -$4.79M +$1.73M +26.6% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-09
Q1 2021 -$13.7M -$1.42M +$6.98M +83.1% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-09
Q4 2020 -$20.6M $2.03M +$6.51M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$27.2M -$7.76M +$8.75M +53% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-10
Q2 2020 -$35.9M -$6.52M +$23.5M +78.3% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-10
Q1 2020 -$59.4M -$8.4M -$47.7M -121% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-10
Q4 2019 -$11.7M -$4.48M +$40.5M +90% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$52.2M -$16.5M -$83.2M -125% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-11
Q2 2019 $31.1M -$30M -$25.8M -613% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-11
Q1 2019 $56.9M $39.3M +$103M Jan 1, 2019 Mar 31, 2019 10-K 2021-03-11
Q4 2018 -$46M -$45M +$27M +37.5% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$73M $66.7M +$52.4M +366% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$125M -$4.22M +$7.44M +63.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$133M -$63.5M -$113M -229% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$20M -$71.9M -$67M -1355% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 $47M $14.3M -$16.9M -54.1% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 $63.9M -$11.7M -$36.2M -147% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 $100M $49.3M +$66.4M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
Q4 2016 $33.7M -$4.95M +$8.56M +63.4% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 $25.1M $31.2M +$44.8M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-15
Q2 2016 -$19.7M $24.5M +$34.2M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-15
Q1 2016 -$53.9M -$17.1M -$6.95M -68.3% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-15
Q4 2015 -$47M -$13.5M -$2.94M -27.8% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-16
Q3 2015 -$44.1M -$13.6M -$5.36M -64.8% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-16
Q2 2015 -$38.7M -$9.69M -$171K -1.8% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-16
Q1 2015 -$38.5M -$10.2M -$2.07M -25.5% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-16
Q4 2014 -$36.5M -$10.6M +$9.04M +46.1% Oct 2, 2014 Dec 31, 2014 10-K 2016-03-15
Q3 2014 -$45.5M -$8.27M +$735K +8.17% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-15
Q2 2014 -$46.2M -$9.52M -$1.97M -26.1% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-15
Q1 2014 -$44.3M -$8.1M -$380K -4.92% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-15
Q4 2013 -$43.9M -$19.6M -$13.6M -225% Sep 29, 2013 Dec 31, 2013 10-K 2015-03-11
Q3 2013 -$30.3M -$9M -$4.05M -81.6% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-11
Q2 2013 -$26.3M -$7.55M -$2.09M -38.3% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-11
Q1 2013 -$24.2M -$7.72M -$2.75M -55.2% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-11
Q4 2012 -$21.4M -$6.04M -$899K -17.5% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-17
Q3 2012 -$20.5M -$4.96M -$1.22M -32.7% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-17
Q2 2012 -$19.3M -$5.46M -$1.18M -27.6% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-17
Q1 2012 -$18.1M -$4.97M -$1.61M -47.9% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-17
Q4 2011 -$16.5M -$5.14M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-18
Q3 2011 -$3.74M +$934K +20% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-18
Q2 2011 -$4.28M -$2.02M -89.3% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-18
Q1 2011 -$3.36M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-18
Q3 2010 -$4.67M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$2.26M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.